Aquestive Therapeutics In... (AQST)
NASDAQ: AQST
· Real-Time Price · USD
2.35
-0.03 (-1.26%)
At close: May 16, 2025, 3:59 PM
2.44
3.61%
After-hours: May 16, 2025, 07:13 PM EDT
Aquestive Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Co-Development and Research Fees Revenue | 1.93M | 1.4M | 1.29M | 1.64M | 1.26M | 4.04M | 5.18M |
| Co-Development and Research Fees Revenue Growth | +37.30% | +8.43% | -20.92% | +29.35% | -68.73% | -22.03% | n/a |
| License and Royalty Revenue Revenue | 15.35M | 5.38M | 2.35M | 5.38M | 14.05M | 6.96M | 24.7M |
| License and Royalty Revenue Revenue Growth | +185.44% | +128.67% | -56.30% | -61.72% | +101.97% | -71.82% | n/a |
| Manufacture and Supply Revenue Revenue | 39.98M | 43.8M | 36.38M | 35.31M | 24.88M | 38.74M | 37.32M |
| Manufacture and Supply Revenue Revenue Growth | -8.74% | +20.42% | +3.02% | +41.92% | -35.77% | +3.81% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 19.07M | 16.01M | 12.13M | 11.36M | 10.69M | 9.55M | 7.38M | 7.36M | 7.46M | 11.81M | 12.46M | 15.59M | 13.02M | 14.98M | 12.13M | 13.13M | 13.23M | 15.58M | 11.8M | 13.89M | 14.61M | 16.47M | 13.71M | 16.25M | 17.91M | 18.7M | 12.35M | 33.65M | 7.57M | 7.57M | 6.16M | 5.22M | 6.13M |
| Selling, General, and Administrative Revenue Growth | +19.13% | +32.02% | +6.78% | +6.24% | +11.93% | +29.32% | +0.34% | -1.27% | -36.89% | -5.19% | -20.07% | +19.71% | -13.08% | +23.51% | -7.65% | -0.73% | -15.09% | +32.02% | -15.05% | -4.92% | -11.30% | +20.13% | -15.59% | -9.28% | -4.25% | +51.50% | -63.31% | +344.54% | +0.05% | +22.79% | +17.96% | -14.77% | n/a |
| Research and Development Revenue | 5.36M | 4.92M | 5.27M | 4.16M | 5.93M | 2.89M | 3.2M | 3.47M | 3.55M | 4.28M | 3.23M | 5.2M | 4.77M | 4.4M | 4.73M | 4.26M | 3.66M | 4.42M | 7.26M | 3.85M | 4.35M | 3.06M | 5.06M | 8.15M | 4.3M | 5.68M | 4.53M | 7.99M | 4.9M | 6.27M | 5.68M | 4.84M | 5.34M |
| Research and Development Revenue Growth | +9.03% | -6.68% | +26.60% | -29.84% | +105.40% | -9.64% | -7.98% | -2.09% | -17.09% | +32.36% | -37.82% | +8.90% | +8.48% | -6.90% | +10.89% | +16.48% | -17.31% | -39.05% | +88.72% | -11.64% | +42.43% | -39.62% | -37.88% | +89.43% | -24.28% | +25.34% | -43.28% | +63.11% | -21.85% | +10.33% | +17.51% | -9.47% | n/a |